A recent study suggests that people who donate blood regularly may have genetic changes in their blood that could in fact reduce the risk of developing cancer. It is conducted by the researchers at the Francis Crick Institute, and the study has now provided new insights into how and why blood cancers develop. The study is published in the journal Blood and was conducted by the scientists from Heidelberg and the German Red Cross blood donation center. There is yet a need for further research to confirm these findings.

What Did The Study Find?

The researchers examined the blood of two groups of healthy male donors in their 60s:

• One group had donated blood three times a year for 40 years.
• The other group had donated only about five times in total.

The goal was to analyze genetic mutations in their blood and assess whether frequent donation had any impact on their genetic makeup.

How Can Blood Donation Affect Stem Cells?

As and when people age, their blood and other cells naturally develop mutations and some of them can also increase the risk of cancer. When anyone donates blood, his or her body compensates by producing new blood cells, which can influence the genetic diversity of stem cells in the bone marrow. The study also found that both groups had a similar number of mutations. For instance the frequent donors had 217 mutations, while the irregular donors had 212 mutations.

However, the nature of these mutations differed. In the frequent donors, 50% of the mutations were of a type not associated with a high risk of blood cancers, compared to only 30% in the irregular donors.

Further laboratory analysis showed that these specific mutations behaved differently from those linked to leukemia, a type of blood cancer. When human blood stem cells with these mutations were injected into mice, they were found to be highly effective at producing red blood cells, which is considered a positive outcome.

Dr. Hector Huerga Encabo, one of the study authors, emphasized that these mutations do not indicate an increased risk of leukemia. The findings suggest that regular blood donation may influence how stem cells evolve, but whether this translates into a lower cancer risk remains uncertain.

Read More: Who Can Donate Blood To Whom?

Limitations

One notable disadvantage is the "healthy-donor effect"—because blood donors are often healthier than the general population, their lower cancer risk could be unrelated to blood donation.

Dominique Bonnet, senior researcher and head of a stem-cell laboratory at the Francis Crick Institute, stressed the need for larger studies with female volunteers to confirm the findings.

Despite ongoing research into potential health benefits for donors, the primary goal of blood donation remains saving lives. NHS Blood and Transplant emphasized that while the study is interesting, further research is required to draw firm conclusions. The organization also noted that blood supplies are currently critically low and encouraged eligible individuals to donate.

Also Read: How Long After a Tattoo or Piercing Can I Donate Blood?

Often, we underestimate the way our brain works and daydreaming has long been seen as a major sign of creativity. Many artists have used their imagination to bring their work to life. However, science offers a different perspective.

Coined in 2002 Dr. Eliezer Somer, those who experience “maladaptive daydreaming” often fantasize about celebrities, historical figures or idealized versions of themselves. Their imaginations are more elaborate, diverse, and complex as compared to other daydreamers.

A 2012 Consciousness and Cognition study found that maladaptive daydreamers spend, on average, 57 percent of their waking hours daydreaming far more than their counterparts.

Dr Somer explains: "The greatest difference is the maladaptive daydreamers reported that the activity interfered with their daily life. They also reported higher rates of attention-deficit and obsessive compulsive symptoms, and more than 80% used kinesthetic activity or movement when daydreaming, such as rocking, pacing or spinning"

He further noted that while everyone experiences moments of mind-wandering, it usually does not interfere with daily life. But maladaptive daydreaming does interfere in regular life. The condition has not been classified as a mental illness and there is no treatment for it yet.

What Do People Say?

Many Reddit users have shared their experiences with maladaptive daydreaming, often asking questions such as: “Is it normal to daydream for such long hours?”

While some responses described daydreaming as a form of dissociation when bored, others relied on music or movies to fuel fantasies of being a “better version” of themselves, often struggling to return to reality.

Common Symptoms Of Maladaptive Daydreaming

Here are some early signs of maladaptive daydreaming to keep an eye out for:

• Compulsive need to daydream
• Avoiding social interaction and activities
• An inability to perform work or other daily tasks
• Extreme feelings of shame or guilt
• Feeling a compulsive need to daydream that you can't control
• Making a conscious effort to stop or lessen daydreaming episodes.
• Intense and extremely vivid daydreams
• Complex and elaborate daydreams, often with many people involved
• Daydreams accompanied by repetitive movements such as pacing
• Prolonged daydreams that may last hours at a time
• A feeling of disconnect or dissociation from people and reality during the episode.

What Does Science Say?

Rachel Bennett, a member of Dr. Somer’s online community, shared she usually dreams up new episodes of her favorite Japanese animé characters and TV shows. She’s also created four families of fictional characters which have grown with her over the years.

“I’d much rather stay home and daydream than go out,” she said.

What Causes Maladaptive Daydreaming?

Dr. Somer noted that about one-quarter of maladaptive daydreamers are trauma survivors who use daydreaming as an escape. Many report family members with similar tendencies, as well as being shy or socially isolated.

Meanwhile, a Harvard Medical study found that 80 percent of maladaptive daydreamers have ADHD, followed by anxiety disorders, depression, and OCD. Researchers believe daydreaming often acts as a coping mechanism for pent-up emotions that cannot be expressed in real life, so they are released through imagination instead.

How Do You Cope With Maladaptive Daydreaming?

Experts emphasize that maladaptive daydreaming is not an extreme condition requiring formal diagnosis, but many people have shared strategies that help:

• Exercise: One forum user reported swimming daily, gradually reaching 2,000 meters, which acted as meditation and grounded them in reality.
• Remove triggers: Avoid activities that spark daydreaming episodes.
• Practice mindfulness: Stay present and aware of thoughts.
• Limit music use: Music is a common trigger.
• Scheduled daydreaming: Set aside specific times with a timer, then consciously exit the session.
• Seek professional help: Therapies such as CBT, DBT, and mindfulness-based stress reduction have shown benefits.
• Stay busy: Engage in tasks to prevent wandering thoughts.
• Improve sleep quality.
• Make daydreams less appealing: Reduce instant gratification.
• Self-development and creativity: Channel imagination into productive outlets.
• Journaling: Record thoughts daily or weekly.
• Practice self-acceptance.
• Find group support.

A new review published in The Lancet highlights how close this shift may be. The study underscores a hard truth: despite having effective medicines for years, global blood pressure control remains disappointingly poor. The real challenge, experts say, is not the absence of drugs—but problems with adherence, health systems, and long-term patient engagement.

The Unrelenting Burden of a Silent Killer

Hypertension continues to be the leading cause of heart attacks, strokes and premature deaths worldwide. The World Health Organization (WHO) defines high blood pressure as readings at or above 140 mm Hg systolic and/or 90 mm Hg diastolic. A normal reading is below 120/80 mm Hg.

The numbers are staggering. Between 2024 and 2025, an estimated 1.4 billion adults aged 30 to 79—roughly one in three people in this age group—are living with hypertension globally. Nearly 44 percent do not even know they have it. Among those diagnosed, fewer than one in four have their blood pressure adequately controlled.

India reflects this alarming trend. The ICMR-INDIAB study (2023) estimated that about 315 million Indians—35.5 percent of the population—have hypertension. Data from NFHS-5 further showed that nearly half of hypertensive men and more than a third of hypertensive women in India do not have their condition under control.

Why Daily Pills Are Falling Short

For decades, hypertension treatment has relied on daily oral medications—often combinations of two or more drugs. These may include ACE inhibitors, angiotensin receptor blockers paired with calcium channel blockers, and thiazide diuretics.

On paper, these regimens are effective. In reality, adherence is the weak link.

Many patients with hypertension also manage diabetes, obesity or high cholesterol. The result is polypharmacy—multiple pills, multiple times a day. Over time, missed doses, side effects and simple “treatment fatigue” erode consistency. Therapeutic inertia—where doctors do not intensify treatment despite poor control—further worsens outcomes.

The Rise of Long-Acting Injectables

This is where long-acting injectable therapies come in. According to Dr Mohit Gupta, cardiologist at G B Pant Hospital and UCMS, the field is now moving toward therapies that may be administered just twice a year.

Unlike traditional medicines that work downstream to reduce blood pressure numbers, these new drugs target upstream molecular pathways that drive hypertension.

One promising approach involves small interfering RNA (siRNA) therapies that inhibit angiotensinogen production in the liver. By silencing this protein, they dampen the renin–angiotensin system—central to blood pressure regulation. Zilebesiran, developed by Roche and Alnylam, is currently in global phase 3 trials.

Another candidate, ziltivekimab by Novo Nordisk, targets inflammatory pathways increasingly linked to cardiovascular risk. There are also newer strategies aimed at selectively modulating aldosterone, a hormone that increases blood volume and pressure.

The appeal is simple: durability. A twice-yearly injection could eliminate the daily burden of pill-taking, improve adherence and provide more stable blood pressure control over time.

Promise, But With Caution

However, excitement is tempered by concern. Cost remains a major question. The recent introduction of inclisiran, an injectable cholesterol-lowering therapy priced between Rs 1.8 and 2.4 lakh annually in India, highlights affordability challenges.

Long-term safety is another critical issue. Hypertension is lifelong. Patients may require these treatments for decades. Experts stress the need for robust long-term data across diverse populations before widespread adoption.

The promise is undeniable. A twice-yearly injection that reliably controls blood pressure could transform preventive cardiology. But its true impact will depend not only on scientific success—but on accessibility, affordability and sustained safety.

A new Lancet study titled Burden of MASLD and liver fibrosis: evidence from the Phenome India cohort published in The Lancet Regional Health - South Asia found that nearly four in 10 Indian adults have fatty liver or what scientifically is known as the metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non as NAFLD or non-alcoholic fatty liver disease.

The study also highlights a more worrying condition that a sizeable proportion of the Indian population already show signs of liver fibrosis. This is an early scarring process that could lead to cirrhosis or liver cancer if left unchecked.

Lancet Study: How Was It Conducted?

The study analyzed data from more than 7,700 adults across 27 cities in India. The study found that 38.9 per cent of participants had MASLD. The authors also noted that this figure is similar to the global estimates, however, is deeply concerning for India's population and size of the country, including the ever-rising burden of diabetes and obesity.

The study also found that 6.3 per cent of people who live with MASLD had significant liver fibrosis, as compared to 1.7 per cent of those without fatty liver.

Read: Indians Are At Most Risk Of Having Fatty Liver Disease, According To Doctor

The study also found that 2.4 per cent of the entire population analyzed showed evidence of significant fibrosis. Why is this concerning? Fibrosis is a strong predicator of future complications. With the advancement of scarring, liver failure, cirrhosis, and liver caser risk also rises.

Lancet Study: Who Are At Risk?

The study found that people with obesity, diabetes, and central or abdominal fat were more likely to have MASLD. Obesity also was seen as the strongest risk factor, with likelihood rising steeply from overweight to severe obesity.

Another factor was also age. Liver fibrosis was seen in adults over the age of 60 years and in people with diabetes, among whom nearly one in ten showed fibrotic changes.

The study also showed that there was a presence of "Lean MASLD", which means it could also happen in people who are not overweight and have a normal body mass index. This is often linked to insulin resistance and visceral fat, which is the fat around internal organs. This tend to accumulate abdominal fat even at lower body weights.

Lancet Study: Can MASLD And Other Liver Diseases Be Prevented?

As per the authors of the study, MASLD is highly modifiable, especially at early stages. There are evidence that show that weight loss reduces liver fat and inflammation. Regular physical activity also improves insulin sensitivity, along with balanced diet. The diet must be consumed without or with very low sugar and ultra-processed food, which helps in control of diabetes and cholesterol and slows down disease progression.

Authors also noted that people should get their fatty liver disease scanned regularly. Especially because MASLD is common among people with obesity and diabetes. There are many non-aggressive tools that could also detect fibrosis early.